Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative products, including the Collink.3D bioink, which has shown superior performance in structured tissue formation compared to traditional animal-derived options, thus positioning the company competitively against established suppliers. The operational U.S.-based logistics center is anticipated to drive incremental sales growth for its BioInk and rhCollagen products, particularly within research institutions and tissue-engineering customers, further enhancing revenue potential. Additionally, the company's strategic partnership with Allergan for the development of dermal fillers and the encouraging data supporting the effectiveness of its rhCollagen for tissue modeling and drug testing underscore the potential for significant market expansion and improved cash flow.

Bears say

CollPlant Biotechnologies Ltd faces significant headwinds reflected in its recent capital raise, which has prompted a disproportionate negative reaction in its stock price. The company’s choice to price its recent financing at $1.25 per share indicates ongoing pressure on its equity and suggests constrained capacity for future capital formation, likely affecting investor confidence. Additionally, lowered forecasts for key products such as Dermal Fillers and BioInk, along with the removal of Breast Implants from operational models, highlight the challenges the company faces in developing its offerings within the regenerative and aesthetic medicine sectors.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.